Mankind Pharma
Market cap ₹91,379 Cr
- P/E
- 44.96
- Day range
- ₹2,196.10 – ₹2,289.60
- 52-week range
- ₹1,909.70 – ₹2,642.00
- Volume
- 6.79 L
- Open
- ₹2,282.90
- Prev close
- ₹2,275.60
Latest results · Q1 FY27(consolidated)Revenue ₹4,031 Cr+12.9%Profit ₹574 Cr+29.1%Margin 14.2%YoY vs the same quarter last year
1 red flag to read up on
- medium
Material exchange filing
Resignation Of Statutory Auditors Of A Material WOS · 28 Sept 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
MANKIND in NSE indices and F&O
F&O margin for one lot of MANKIND (250 shares)Research profile
Composite 59 / 100Factor percentiles
Derived metrics
- Earn. yield
- 2.2%
- Graham no.
- ₹677.04
- vs Graham
- -69.4%
- ROE ÷ P/B
- 2.3%
- 12-1 mom.
- +1.7%
- Return / vol
- -0.35
- Magic Formula
- #473
- Piotroski
- 5/6
- FCF yield
- 2.6%
- PEG
- 1.42
Appears in 7 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 67 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.19 L Cr | 34.68 | 5.02 | 14.8% | 21.0% | 29.0% | 0.06 | +10.5% |
| Divi's LaboratoriesDIVISLAB | ₹2.38 L Cr | 81.21 | 14.52 | 16.2% | 22.0% | 41.0% | 0.00 | +27.8% |
| Torrent PharmaTORNTPHARM | ₹1.72 L Cr | 76.43 | 9.37 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Zydus LifesciencesZYDUSLIFE | ₹1.13 L Cr | 25.17 | 4.20 | 20.1% | 21.0% | 24.0% | 0.46 | +22.0% |
| Apollo HospitalsAPOLLOHOSP | ₹1.11 L Cr | 53.19 | 11.54 | 22.6% | 17.0% | 16.0% | 0.90 | +20.6% |
| CiplaCIPLA | ₹1.08 L Cr | 32.09 | 3.12 | 11.8% | 15.0% | 17.0% | 0.02 | +2.3% |
| Laurus LabsLAURUSLABS | ₹1.06 L Cr | 97.38 | 20.06 | 18.2% | 18.0% | 32.0% | 0.48 | +29.0% |
| Mankind PharmaMANKIND | ₹91,379 Cr | 44.96 | 5.60 | 12.7% | 14.0% | 26.0% | 0.39 | +12.9% |
| Sector median | ₹23,579 Cr | 41.61 | 5.60 | 15.1% | 17.0% | 25.0% | 0.16 | +20.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 5d agoHeadlines about Mankind Pharma from the last two weeks in the financial press. Stories belong to their publishers; Parasram India does not endorse them.
Key metrics
- P/E (TTM)
- 42.9
- EPS (TTM)
- ₹49.42
- Price / Book
- 5.60
- ROE (FY26)
- 12.7%
- ROCE (latest year)
- 14%
- Dividend yield
- 0.05%
Moving averages (NSE)
- 20-day
- ₹2,398.94
- Price below
- 50-day
- ₹2,377.67
- Price below
- 200-day
- ₹2,307.61
- Price below
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- DII
- FII
- Public
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Financial statements
| Line item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,708 | 2,607 | 2,422 | 2,868 | 3,061 | 3,199 | 3,079 | 3,570 | 3,697 | 3,567 | 3,443 | 4,031 |
| Expenses | 2,025 | 2,000 | 1,836 | 2,196 | 2,214 | 2,383 | 2,396 | 2,724 | 2,776 | 2,648 | 2,513 | 2,974 |
| Operating Profit | 683 | 606 | 586 | 672 | 847 | 816 | 683 | 847 | 921 | 919 | 930 | 1,056 |
| OPM % | 25% | 23% | 24% | 23% | 28% | 26% | 22% | 24% | 25% | 26% | 27% | 26% |
| Other Income | 63 | 75 | 94 | 108 | 109 | 87 | 249 | 83 | 94 | -31 | 94 | 49 |
| Interest | 9 | 9 | 9 | 11 | 7 | 221 | 191 | 171 | 170 | 157 | 142 | 110 |
| Depreciation | 96 | 110 | 100 | 103 | 100 | 187 | 231 | 219 | 222 | 223 | 223 | 226 |
| Profit before tax | 641 | 562 | 572 | 666 | 849 | 495 | 511 | 540 | 624 | 509 | 659 | 769 |
| Tax % | 20% | 18% | 17% | 18% | 22% | 22% | 17% | 18% | 17% | 19% | 15% | 25% |
| Net Profit | 511 | 460 | 477 | 543 | 659 | 385 | 425 | 445 | 520 | 414 | 559 | 574 |
| EPS in Rs | ₹12.51 | ₹11.33 | ₹11.76 | ₹13.39 | ₹16.31 | ₹9.22 | ₹10.20 | ₹10.62 | ₹12.39 | ₹9.90 | ₹13.43 | ₹13.75 |
From company filings, updated 24 Oct 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+25 days since Mar 2021
-50 days since Mar 2021
-16 days since Mar 2021
-8 days since Mar 2021
-72 days since Mar 2021
Strengths, risks & growth
Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products. [1]
Strengths
- Company has reduced debt.
Risks
- Promoter holding has decreased over last 3 years: -3.88%
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- +18%
- 3 Years
- +18%
- TTM
- +14%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- +11%
- 3 Years
- +17%
- TTM
- +13%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- —
- 3 Years
- +9%
- 1 Year
- -9%
Return on Equity
- 10 Years
- —
- 5 Years
- +17%
- 3 Years
- +16%
- Last Year
- +13%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 72.66% | 72.66% | 72.63% | 72.62% | -0.01 pp |
| FII | 11.34% | 10.24% | 9.45% | 9.37% | -0.08 pp |
| DII | 13.26% | 14.46% | 15.39% | 15.54% | +0.15 pp |
| Public | 2.75% | 2.63% | 2.53% | 2.46% | -0.07 pp |
Filed with NSE for Sept 2026: promoters 72.62%, public 27.38% · XBRL filing
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 11.31% (+0.44 pp)- Promoters72.6%
- Foreign institutions9.4%
- Mutual funds11.3%
- Insurance1.4%
- Other domestic institutions2.9%
- Retail1.3%
- Others1.2%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| SBI Large Cap Fund | 1.08% | 1.95% | +0.06 pp |
| Nippon India Growth Mid Cap Fund | 1.04% | 1.95% | +0.19 pp |
| HDFC Large Cap Fund | 0.73% | 1.84% | +0.05 pp |
| Nippon India Large Cap Fund | 0.57% | 1.04% | +0.20 pp |
| Aditya Birla SL Flexi Cap Fund | 0.55% | 1.85% | +0.27 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.
Risk & trend
From 275 daily sessions to 23 Oct 2026.
Risk
- Volatility (1Y)
- 26.5%
- Downside volatility
- 24.8%
- Worst 5% of days
- 2.7%
- Average of that tail
- 3.5%
- Max drawdown (1Y)
- 27.6%
- Below its peak
- 16.8%
Against the market
- Beta vs Nifty 50
- 0.65
- Correlation
- 0.32
- Relative strength (3M)
- -8.2%
- ATR (14)
- 3.1%
Return
- Return 1M
- -10.8%
- Return 3M
- -13.5%
- Return 6M
- -1.0%
- Return 1Y
- -9.2%
- vs 200-day average
- -4.1%
Momentum
- RSI (14)
- 34.6
- MACD histogram
- -22.99
- Stochastic %K
- 4.8
- ADX (14)
- 24.1
- +DI / −DI
- 12.1 / 25.1
- Money flow index
- 14.8
Participation
- Delivery (20d avg)
- 55.8%
- vs its 60-day baseline
- -0.5 pts
- Volume vs 20-day
- +0.2σ
- Close vs day's VWAP
- -0.3%
- 52-week position
- 39 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 31 Mar 2026.
Piotroski F-Score
5 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — passed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — passed
- Free cash flow
- ₹2,384 Cr
- FCF yield
- 2.6%
- Cash conversion
- 1.61
- Accruals ratio
- -0.042
- Net debt
- ₹5,920 Cr
- Net debt / equity
- 0.36
- EV / sales
- 6.60
- PEG
- 1.42
- Capex intensity
- 5.2%
- Revenue CAGR
- 11.8%
- Profit CAGR
- 31.7%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividendNot available — not reported in this filing
Interim Dividend - Re 1 Per Share
8 Aug 2025ex-date
Company announcements
Due to a technical issue, the meeting link provided in the earlier intimation regarding "Rescheduling of the Earnings Conference Call for Q2 & H1 FY27", uploaded today at 15:39:16 IST, ....
Please find attached Intimation regarding Schedule of Analyst/ Institutional Investors Meet
Please find attached intimation regarding rescheduling of Earnings Conference Call for Q2 & H1 FY27
Intimation regarding payment of interest and redemption of Non-Convertible Debentures ("NCD")
Please find attached intimation regarding ESG Rating
Please find attached press release titled "Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies".
Please find attached intimation regarding investment by the Company.
Please find attached outcome of Board Meeting held on October 15, 2026.
Please find attached intimation regarding Earnings Conference Call for Q2 & H1 FY27.
Please find attached certificate under Regulation 74(5) of the SEBI (DP) Regulations, 2018 for the quarter ended on September 30, 2026.
Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2026 ,inter alia, to consider and approve the unaudited standalon and ....
Please find attached intimation regarding resignation of Statutory Auditors of the Bharat Serums and Vaccines Limited, a matterial wholly owned subsidiary company.
Please find attached, the intimation of clsoure of the trading window.
Please find attached Voting Results of Postal Ballot and Scrutinizer's Report
Please find attached Voting Results of Postal Ballot and Scrutinizer's Report
Filed with BSE (scrip 543904); the last 45 days. Documents open at bseindia.com.
Documents
Earnings calls
- Aug 2026TranscriptSlidesRecording
- May 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlidesRecording
- Nov 2025TranscriptSlidesRecording
- Aug 2025TranscriptSlidesRecording
- May 2025TranscriptSlides
Credit ratings
- Rating update · 12 May from icra
- Rating update · 22 Apr from care
- Rating update · 24 Feb from icra
- Rating update · 16 Jan from icra
- Rating update · 13 Nov 2025 from icra
- Rating update · 29 Oct 2025 from crisil
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 31 Jul 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Mankind Pharma: common questions
Answered from the figures on this page.
